logo
Nonprofit restores prairie, bison grazing at Illinois' Nachusa Grasslands

Nonprofit restores prairie, bison grazing at Illinois' Nachusa Grasslands

CBS News23-05-2025
Drive two hours west of the Loop, and pristine prairie will appear.
The Nachusa Grasslands are located in Lee and Ogle counties, 3 miles northwest of the town of Franklin Grove. The Nature Conservancy replanted and restored the prairie, and the nonprofit also manages the Nachusa Grasslands and the animals that graze there.
Behind the gates to the prairie is a piece of the past.
"There's really only a few thousand acres of tallgrass prairie like this left in Illinois," said research scientist Elizabeth Bach.
But when Bach rolls over rolling hills of the Nachusa Grasslands in a sport-utility vehicle, she sees the future.
"And that future is built on the foundations of our past," she said.
That foundation is one where the prairie flourished, and buffalo roamed.
At the Nachusa Grasslands, there are more than 4,000 acres of restored tallgrass prairie — and one herd of bison.
"Grazing is something, especially from bison, that's been absent from this state of Illinois since the 1870s," Bach said.
But in the 2014, the Nature Conservancy — a global environmental nonprofit — brought bison back.
"The bison at Nachusa Grasslands have access to 1500 acres," said Bach.
As a research scientist, Bach studies how the herd of about 100 bison impacts the prairie.
"This is the best part of my job, is to get to be out here, and I look at these plants every year," Bach said.
Every spring, as calves are born and flowers bloom, Bach checks on plots and areas where bison graze — and where they don't.
"We can track how the plant community without grazing compares to the plant community with grazing," Bach said.
Bach sees a noticeable difference.
"Areas where the bison are grazing heavily will keep a shorter structure for the grasses and plants there, and that's a good thing for certain types of birds and insects and small mammals and reptiles," she said.
Just by grazing and wallowing — the behavior where they roll around on their backs — the big mammals create microhabitats.
"We are seeing changes in the abundance of certain insects like ground beetles and dung beetles," said Bach.
And when the bison share their winter coats, their fur helps birds build their homes.
"To keep those baby birds warm on these cold spring nights," Bach said.
At the Nachusa Grasslands, the buffalo roam — and restore.
"What we're really trying to do is to set up these native Illinois plants and animals for success into the future," Bach said.
The Nature Conservancy keeps the herd to about 100 bison. They transfer surplus animals to the Intertribal Buffalo Council, whose mission is to restore buffalo to tribal lands.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke
Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke

Associated Press

time5 hours ago

  • Associated Press

Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke

The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of proportion of patients demonstrating functional independence at 90 days and is being conducted under a Special Protocol Assessment (SPA) with the FDA. Sovateltide, a potential first-in-class, highly selective endothelin-B (ETB) receptor agonist, has previously demonstrated significant improvement in stroke patients compared to standard of care in a Phase 3 trial that served as the basis for regulatory approval in India. Recent $25 million equity investment from Sun Pharmaceutical Industries Limited, provides sufficient capital to complete the Phase 3 trial. WILLOWBROOK, Ill., July 29, 2025 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ('Pharmazz' or the 'Company'), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, today announced that the first patient has been enrolled and treated in the pivotal Phase 3 RESPECT-ETB clinical trial assessing the safety and efficacy of sovateltide for the treatment of acute cerebral ischemic stroke ( NCT05691244 ). Sovateltide represents a potential breakthrough as a first-in-class endothelin-B receptor agonist, uniquely promoting neurovascular remodeling—generating new neurons (neurogenesis), blood vessels (angiogenesis), and enhancing mitochondrial function. 'There has not been a new FDA approved non-thrombolytic therapy for stroke in over 30 years. We have already shown promising results in our previous Phase 3 study, which showed that sovateltide could be a meaningful advance over standard of care to promote a fast recovery and improve neurological outcomes in cerebral ischemic stroke patients,' said Emeritus Prof. Anil Gulati, CEO and Founder of Pharmazz. 'We have now treated the first patient in our US-based Phase 3 clinical trial and have sufficient capital to complete this study to further cement the potential for sovateltide to transform the treatment of cerebral ischemic stroke.' 'There is a massive and ongoing medical burden associated with ischemic stroke, which continues to be a leading cause of long-term disability, affecting hundreds of thousands of patients each year,' said Dr. Thomas Devlin, MD, PhD, FSVIN, physician executive of Neurosciences and medical director at CHI Memorial Stroke and Neuroscience Center, and principal investigator of the Phase 3 trial. 'Current treatment options remain limited, underscoring the critical need for novel therapies. Given the promising results already demonstrated with sovateltide, this rigorous Phase 3 study represents an important step toward addressing this urgent unmet medical need.' Phase 3 Trial of Sovateltide for Stroke Covered by Special Protocol Assessment Sovateltide is a first-in-class endothelin-B receptor (ETBR) agonist to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptoms. Pharmazz has received agreement from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the study design and statistical analysis plan of its Phase 3 clinical trial of sovateltide for the treatment of acute cerebral ischemic stroke patients. Pharmazz has now enrolled and treated the first patient in its Phase 3 trial, RESPECT-ETB ( ID: NCT05691244 ). The Phase 3 clinical trial is designed to enroll a total of 514 stroke patients at 65 sites in the US, Germany, Spain, and the UK. The primary endpoint is the proportion of patients demonstrating functional independence post-stroke, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after stroke onset. About Sovateltide and Stroke Stroke is a leading cause of long-term disability in the United States, affecting more than 795,000 people each year, and reduces mobility in more than half of stroke survivors over the age of 651. Sovateltide is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Sovateltide is unique because its action site is the neural progenitor cells. Sovateltide promotes neurovascular remodeling by inducing the formation of new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. The Phase 3 trial that served as the basis for approval in India was published in 2024 and showed that the sovateltide group (n=80) had a significantly greater number of cerebral ischemic stroke patients with lower mRS and NIHSS scores at 90 days post-treatment than the control group (n=78).2 About Pharmazz, Inc. Pharmazz is a privately held company developing novel products in critical care medicine. Pharmazz, Inc. has obtained marketing authorization for two of its first-in-class drug molecules, centhaquine and sovateltide, for the treatment of hypovolemic shock and ischemic stroke, respectively, in India. In addition, the US Food and Drug Administration (FDA) has approved two phase III INDs for centhaquine as an agent for hypovolemic shock and sovateltide for cerebral ischemic stroke. Additional information may be found on the Company's website, Disclaimer: Statements in this 'Document' describing the Company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be 'forward-looking statements' within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: 1 Centers for Disease Control. 2 Drugs. 2024 Nov 15;84(12):1637–1650. doi: 10.1007/s40265-024-02121-5

Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand
Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand

Yahoo

time7 hours ago

  • Yahoo

Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand

The Freepod® nasal spray pump, globally used with the Otrivin® brand, is now made from 52% bio-based feedstock CRYSTAL LAKE, Ill., July 29, 2025--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. Reinforcing circularity in pharmaceutical packaging Aptar Pharma's Freepod® spray pump used with Haleon's Otrivin® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device. ISCC PLUS certified manufacturing and supply chain Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod® components. Partnership for a more sustainable approach The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin® Freepod® winning the World Packaging Award in 2019 for its innovative and sustainable design. The use of bio-based or renewable feedstocks for the Otrivin® products with Freepod® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma's Freepod® for Otrivin®, available globally, demonstrates Aptar's commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon's latest microdroplet technology, which is being rolled out globally since 2023. "At Aptar, sustainability is not just a responsibility - it's a strategic advantage," commented Gael Touya, President of Aptar Pharma. "The launch of Freepod® Futurity™ reflects our commitment to developing solutions that respond to consumers' increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient." With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals. *ISCC Plus certified bio-based feedstock, mass balance approach.**The end point for the goal delivery period is the end of the 2025 calendar year. About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding. View source version on Contacts Media Contact: Ciara JacksonAptar Pharma+49 151 1951

To stay sharper while aging, get active, challenge your brain, and eat healthy
To stay sharper while aging, get active, challenge your brain, and eat healthy

Washington Post

time16 hours ago

  • Washington Post

To stay sharper while aging, get active, challenge your brain, and eat healthy

WASHINGTON — It's official: Older Americans worried about cognitive decline can stay sharper for longer by exercising both their bodies and their brains and eating healthier. That's according to initial results released Monday from a rigorous U.S. study of lifestyle changes in seniors at risk of developing dementia . People following a combination of healthier habits slowed typical age-related cognitive decline — achieving scores on brain tests as if they were a year or two younger, researchers reported in JAMA and at the Alzheimer's Association International Conference. It's not too late to get started -- study participants were in their 60s and 70s -- and it doesn't require becoming a pickleball champ or swearing off ice cream. 'It was the first time I felt like I was doing something proactive to protect my brain,' said Phyllis Jones, 66, of Aurora, Illinois, who joined the study after caring for her mother with dementia and struggling with her own health problems. It's too soon to know if stalling age-related decline also could reduce the risk of later Alzheimer's or other forms of dementia. But Jones and other study participants underwent brain scans and blood tests that researchers now are analyzing for clues – such as whether people also saw a reduction in Alzheimer's-related protein buildup. 'We're all on a cognitive aging clock and anything we can do to slow that clock down, to me, that is a significant benefit,' said Laura Baker of Wake Forest University School of Medicine, who led the study. Doctors have long encouraged physical activity and a healthy diet for brain fitness. Those steps fight high blood pressure and cholesterol, heart disease and diabetes, factors that increase the risk of dementia. But until now the strongest evidence that specific lifestyle changes later in life could improve how people perform on brain tests came from a study in Finland. Would it work for a more sedentary and culturally diverse U.S. population? With funding from the Alzheimer's Association and the National Institute on Aging, Baker's team tested the strategy for two years in 2,100 adults ages 60 to 79. Half of participants were randomly assigned to group classes for exercise and dietary changes plus brain-challenging homework – with peer support and coaches tracking their progress. They did a half-hour of moderately intense exercise four times a week -- plus twice a week, they added 10 to 15 minutes of stretching and 15 to 20 minutes of resistance training. They followed the 'MIND diet' that stresses lots of leafy greens and berries plus whole grains, poultry and fish. Nothing is banned but it urges limiting red meat, fried or 'fast food' and sweets, and substituting olive oil for butter and margarine. They also had to meet someone or try something new weekly and do brain 'exercises' using an online program called Brain HQ. Other study participants, the control group, received brain-healthy advice and minimal coaching — they chose what steps to follow. Both improved but the groups fared significantly better. Combining social engagement with exercise and dietary steps may be key, said Jessica Langbaum of the Banner Alzheimer's Institute, who wasn't involved with the study. 'Americans want to have that one easy thing – 'If I just eat my blueberries,'' Langbaum said. 'There is no one magic bullet. It is a whole lifestyle.' Moderately intense physical activity means raising your heart rate and panting a bit yet still able to talk, said Wake Forest's Baker. Pick something safe for your physical capability and start slowly, just 10 minutes at a time until you can handle more, she cautioned. Make it something you enjoy so you stick with it. Likewise there are many options for brain exercise, Baker said – puzzles, joining a book club, learning an instrument or a new language. Jones, a software engineer-turned-tester, learned she loves blueberry-spinach smoothies. Her favorite exercise uses an at-home virtual reality program that lets her work up a sweat while appearing to be in another country and communicating with other online users. Researchers will track study participants' health for four more years and the Alzheimer's Association is preparing to translate the findings into local community programs. Will people with stick with their new habits? Jones lost 30 pounds, saw her heart health improve and feels sharper especially when multitasking. But she hadn't realized her diet slipped when study coaching ended until a checkup spotted rising blood sugar. Now she and an 81-year-old friend from the study are helping keep each other on track. The lifestyle change 'did not just affect me physically, it also affected me mentally and emotionally. It brought me to a much better place,' Jones said. —- The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store